3805 Old Easton Road
Doylestown, PA 18902
United States
617 463 9385
https://www.aprea.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 7
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Oren Gilad Ph.D. | Co-Founder, CEO, President & Director | 796.95k | N/A | 1968 |
Mr. John P. Hamill CPA | Senior VP, CFO, Principal Accounting Officer & Secretary | 610.23k | N/A | 1964 |
Dr. Dansu Li Ph.D. | Head of Technology | N/A | N/A | N/A |
Dr. Lars B. Abrahmsen Ph.D. | Senior VP & Chief Scientific Officer | N/A | N/A | 1957 |
Mr. Brian Wiley | Senior Vice President of Corporate Development & Strategy | N/A | N/A | 1968 |
Dr. Michel Afargan Ph.D. | Head of Pharmacology Development | N/A | N/A | N/A |
Mr. Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor | N/A | N/A | 1962 |
Dr. Nadeem Q. Mirza M.D., M.P.H. | Chief Medical Officer | N/A | N/A | N/A |
Ms. Andrea Epstein | Controller | N/A | N/A | N/A |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Aprea Therapeutics, Inc.’s ISS governance QualityScore as of 1 May 2024 is 8. The pillar scores are Audit: 3; Board: 7; Shareholder rights: 8; Compensation: 9.